Global HIV Market Remains Attractive for Pharma Companies, Says Black Swan Analysis in Its Report Published at MarketPublishers.com
19 Oct 2016 • by Natalie Aster
LONDON – The human immunodeficiency virus (HIV) is known as a lentivirus, which causes chronic viral infection. HIV damages a human’s immune system and also prevents the body from fighting off infections and organisms. If HIV is not diagnosed at an early stage and is not treated, the body goes on to develop acquired immunodeficiency syndrome (AIDS), the final stage of HIV. Commonly, HIV is a sexually transmittable infection. A contact with infected blood, usage of contaminated needles from an infected person, breast milk and infected blood products, perinatal transmission, among others, are also major routs of HIV transmission.
Globally, the HIV market is highly attractive for pharmaceutical companies, involved in the development of new drugs, as despite a great number of approved drugs, high unmet needs for efficacious medications still exist. Didanosine, zidovudine, stavudine and lamivudine are the key generic types of HIV drugs, together accounting for a share of nearly 46% of the global HIV market.
The market for HIV is likely to gain traction in the years to come. New HIV medications (able to increase a patients’ life expectancy and improve their quality of life) are expected to enter the marketplace.
Region-wise, North American takes lead in the global HIV market, accounting for a 50% revenue share. It is followed by Europe with a 30% revenue share. Growth in both these regions is encouraged by such factors as high affordability of drugs and broad health insurance coverage. Given poor healthcare standards, Africa, Asia and Latin America remain untapped markets for HIV treatment.
Latest research report “Epiomic Epidemiology Series: HIV Forecast in 8 Major Markets 2016-2026” prepared by Black Swan Analysis offers an all-round review of the current situation in the HIV market across 8 major markets (namely the USA, France, Germany, Italy, Spain, the UK, Brazil and Japan); it contains updated statistics split by 5-year age cohort and gender. Besides, the report also contains a general overview of the disease, covers HIV risk factors, offers details on the disease diagnosis and prognosis as well as touches upon specific variations by geography and ethnicity. Trustworthy insights into clinical trials are provided in the report together with detailed overviews of the key existing treatment options and new product launches, and a snapshot of the recent industry developments and strategies. Additionally, the report offers future projections for the HIV market up till 2026.
More insightful research reports elaborated by Black Swan Analysis are provided at its page.